Serum Institute of India
Serum Institute of India Pvt. Ltd. is the vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by the Serum Institute are accredited by the World Health Organization, Geneva and are being used in around 140 countries across the globe in their national immunization programs, saving millions of lives throughout the world.
Hervolution Therapeutics focuses on developing first-in-class immunotherapies to combat tumors from within. The company leverages Human Endogenous Retroviral proteins (HERVs) to create rationally designed immune therapeutics targeting the dark genome. Hervolution Therapeutics aims to address hidden enemies within the human body by pioneering innovative biotechnology solutions.
IntegriMedical is a global manufacturer of medical devices, specializing in innovative needle-free drug delivery systems. The company focuses on developing and marketing advanced medical devices, particularly needle-free cartridge injectors that employ high-velocity mechanical power to deliver RNA-based biologics and medications. These devices are designed for both intramuscular and subcutaneous administration, addressing the needs of patients who experience needle phobia. By utilizing jet stream technology, IntegriMedical's products aim to minimize pain and enhance user convenience, making them compact, portable, and easy to use. This approach not only improves patient comfort but also enhances safety for healthcare professionals.
Codagenix, Inc. is a biotechnology company specializing in the development of live-attenuated viral vaccines targeting various diseases, including influenza, dengue, respiratory syncytial virus, and polio. Founded in 2009 and based in Farmingdale, New York, the company leverages its innovative Synthetic Attenuated Virus Engineering (SAVE) platform, which employs computer-based rational design to re-engineer the genomes of viruses. This technology enables the creation of vaccines that incorporate specific target antigens within an attenuated viral backbone. In addition to human vaccines, Codagenix also develops vaccines for agricultural and companion animals, contributing to a broader approach to viral disease management.
Oxford BioMedica is a biopharmaceutical company based in Oxford, United Kingdom, specializing in gene and cell therapy. It is recognized for its expertise in lentiviral vector technology, which allows for the integration of therapeutic genes into non-dividing cells, including neurons and retinal cells. The company operates in two main segments: Platform and Product. The Platform segment focuses on bioprocessing and development services for third parties, while the Product segment is dedicated to the clinical and preclinical development of gene and cell therapies targeting a range of diseases, particularly those affecting the ocular and central nervous system. Oxford BioMedica's product pipeline includes several candidates, such as OXB-302 for haematological tumors and OXB-203 for wet age-related macular degeneration, among others. The company has established partnerships with major pharmaceutical firms, including Novartis and Bristol Myers Squibb, to enhance its research and development efforts. Founded in 1995, Oxford BioMedica aims to transform treatment options for diseases with limited or no existing therapies.
SCHOTT Poonawalla is a Mumbai-based manufacturer specializing in pharmaceutical glass packaging. The company produces a variety of products tailored for the pharmaceutical industry, including neutral glass containers such as vials, pre-fillable syringes, ampoules, and cartridges. By offering these parenteral packaging systems, SCHOTT Poonawalla supports the needs of its clients in delivering safe and effective pharmaceutical solutions.
X-Vax Technology is a biotechnology company based in Jupiter, Florida, established in 2015. The company specializes in the preclinical and clinical development of vaccines designed to combat mucosal infections caused by pathogens such as herpes, influenza, tuberculosis, and HIV, which impact millions globally. X-Vax is advancing a herpes vaccine candidate based on a genetically modified HSV-2 virus that lacks glycoprotein D. This innovative approach aims to prevent infections from both herpes type 1 and type 2 by inducing antibodies that facilitate antibody-dependent cell-mediated killing, thereby creating a robust immune response against these viruses.
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
Nanotherapeutics is a privately held specialty biopharmaceutical company with full product development, cGMP manufacturing capabilities, and a proprietary pipeline. The Company's technologies can be used with all drug types ranging from small molecules to proteins and peptides. These technologies can be employed with new chemical entities or with generic drugs and can be used with the spectrum of existing drug types ranging from small synthetic molecules to large recombinant macromolecules.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.